HRP20251420T1 - Gpr52 modulatorski spojevi - Google Patents

Gpr52 modulatorski spojevi

Info

Publication number
HRP20251420T1
HRP20251420T1 HRP20251420TT HRP20251420T HRP20251420T1 HR P20251420 T1 HRP20251420 T1 HR P20251420T1 HR P20251420T T HRP20251420T T HR P20251420TT HR P20251420 T HRP20251420 T HR P20251420T HR P20251420 T1 HRP20251420 T1 HR P20251420T1
Authority
HR
Croatia
Prior art keywords
disorder
disorders
salt
disease
compound
Prior art date
Application number
HRP20251420TT
Other languages
English (en)
Croatian (hr)
Inventor
Stephen Paul Watson
Nigel Alan Swain
Michael Alistair O'brien
Original Assignee
Nxera Pharma Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nxera Pharma Uk Limited filed Critical Nxera Pharma Uk Limited
Publication of HRP20251420T1 publication Critical patent/HRP20251420T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20251420TT 2021-09-15 2022-09-15 Gpr52 modulatorski spojevi HRP20251420T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2113186.7A GB202113186D0 (en) 2021-09-15 2021-09-15 GPR52 Modulator compounds
EP22778038.4A EP4401833B1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds
PCT/GB2022/052328 WO2023041909A1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
HRP20251420T1 true HRP20251420T1 (hr) 2026-01-02

Family

ID=78149263

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20251420TT HRP20251420T1 (hr) 2021-09-15 2022-09-15 Gpr52 modulatorski spojevi

Country Status (22)

Country Link
US (1) US20240376070A1 (https=)
EP (1) EP4401833B1 (https=)
JP (1) JP2024535860A (https=)
KR (1) KR20240058852A (https=)
CN (1) CN117999258A (https=)
AU (1) AU2022348201A1 (https=)
CA (1) CA3232606A1 (https=)
CL (1) CL2024000742A1 (https=)
DK (1) DK4401833T3 (https=)
ES (1) ES3053759T3 (https=)
FI (1) FI4401833T3 (https=)
GB (1) GB202113186D0 (https=)
HR (1) HRP20251420T1 (https=)
IL (1) IL311015A (https=)
LT (1) LT4401833T (https=)
MX (1) MX2024003248A (https=)
PL (1) PL4401833T3 (https=)
PT (1) PT4401833T (https=)
RS (1) RS67399B1 (https=)
SI (1) SI4401833T1 (https=)
SM (1) SMT202500449T1 (https=)
WO (1) WO2023041909A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180004193A (ko) 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
JP7394747B2 (ja) * 2017-09-13 2023-12-08 ノバルティス アーゲー ジフェニル誘導体及びその使用
CA3156474A1 (en) * 2019-11-08 2021-05-14 Heptares Therapeutics Limited GPR52 MODULATING COMPOUNDS
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds

Also Published As

Publication number Publication date
AU2022348201A1 (en) 2024-03-28
KR20240058852A (ko) 2024-05-07
EP4401833A1 (en) 2024-07-24
LT4401833T (lt) 2025-12-10
WO2023041909A1 (en) 2023-03-23
GB202113186D0 (en) 2021-10-27
JP2024535860A (ja) 2024-10-02
FI4401833T3 (fi) 2025-11-25
SI4401833T1 (sl) 2026-01-30
EP4401833B1 (en) 2025-10-22
DK4401833T3 (da) 2025-11-17
PT4401833T (pt) 2025-11-14
CN117999258A (zh) 2024-05-07
PL4401833T3 (pl) 2026-02-16
RS67399B1 (sr) 2025-11-28
MX2024003248A (es) 2024-04-02
ES3053759T3 (en) 2026-01-26
CL2024000742A1 (es) 2024-09-27
IL311015A (en) 2024-04-01
US20240376070A1 (en) 2024-11-14
SMT202500449T1 (it) 2026-01-12
CA3232606A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
HRP20251420T1 (hr) Gpr52 modulatorski spojevi
CN104892672B (zh) 手性螺环膦-氮-硫三齿配体及其制备方法和应用
HRP20241375T1 (hr) Spojevi modulatora gpr52
CN109651225B (zh) 一种1-甲基-3-吗啡啉基-4-芳巯基马来酰亚胺化合物的制备方法
CN106220533A (zh) 一种利用酮、胺和二氧化碳合成氨基甲酸酯的方法
CN111393350A (zh) 一种n-甲基-3-取代苄巯基-4-吗啉基马来酰亚胺化合物的合成方法
CN111333564B (zh) 一种3-烷巯基-1-甲基-4-吗啉基马来酰亚胺化合物的合成方法
JP2024535860A5 (https=)
ES2849425T3 (es) Método de fabricación de alcohol de cadena larga de ciclohexenona de alta pureza
CN103664821B (zh) 一种基于邻氨基苯硫酚环化的苯并噻唑类化合物制备方法
ES2272786T3 (es) Procedimiento para la sintesis selectiva de trietilendiamina.
Pavia et al. Benzo-fused bicyclic imides
CN111440109B (zh) 一种n-甲基-3-甲巯基-4-胺基马来酰亚胺化合物的制备方法
Herndon et al. Pericyclic reactions of cyclopropylcarbene-chromium complexes
CN105693598A (zh) 一种铱催化氢化合成3-哌啶酮衍生物的方法
RU2024109992A (ru) Соединения-модуляторы gpr52
CN104262122B (zh) 一种1,4-丁烯二酮类化合物的合成方法
TWI546312B (zh) 以無溶劑製程製備環磷醯胺之方法
CN110845466A (zh) 氧杂环壬二烯衍生物、其药物组合物、其制备方法及用途
CN104030994A (zh) 1,2,3—三唑类化合物的合成方法
Pinna et al. Synthesis, modelling, and μ-opioid receptor affinity of N-3 (9)-arylpropenyl-N-9 (3)-propionyl-3, 9-diazabicyclo [3.3. 1] nonanes
Weber et al. Crystalline Hosts Based on the Assembly of Anthracene and Bulky Alcoholic Groups–Host Synthesis, Complex Formation, and X‐ray Crystal Structures of Several Inclusion Compounds
CN104650025B (zh) 一种苯并氧杂环庚三烯类化合物的合成方法
MX2008015050A (es) Proceso para sintetizar compuestos de piperazina-piperidina.
CN104844565B (zh) 一种基于硫粉合成噻蒽的方法